Abstract:figure legend A head‐to‐head comparative analysis of two new mouse models of non‐ischaemic heart failure with reduced ejection fraction (HFrEF) and cardiometabolic heart failure with preserved ejection fraction (HFpEF) disclosed key differences regarding several pathophysiological features. The HFrEF left ventricle was characterized by systolic dysfunction, with accompanying fibrosis and pronounced cardiomyocyte hypertrophy, and HFrEF cardiomyocytes exhibited impaired calcium handling and damaged mitochondria. In contrast, the HFpEF left ventricle experienced a substantial increase in myocardial stiffness and a heightened inflammatory state, with a subtler hypertrophic response. In contrast to HFrEF, HFpEF cardiomyocytes displayed a rather enhanced but asynchronous calcium release, with comparably impaired mitochondria. Protein hyperacetylation was considerably more drastic in the HFpEF heart. Heart failure (HF) is a heterogeneous condition that can be categorized according to the left ventricular ejection fraction (EF) into HF with reduced (HFrEF) or preserved (HFpEF) EF. Although HFrEF and HFpEF share some common clinical manifestations, the mechanisms underlying each phenotype are often found to be distinct. Identifying shared and divergent pathophysiological features might expand our insights on HF pathophysiology and assist the search for therapies for each HF subtype. In this study, we evaluated and contrasted two new murine models of non‐ischaemic HFrEF and cardiometabolic HFpEF in terms of myocardial structure, left ventricular function, gene expression, cardiomyocyte calcium handling, mitochondrial polarization and protein acetylation in a head‐to‐head fashion. We found that in conditions of similar haemodynamic stress, the HFrEF myocardium underwent a more pronounced hypertrophic and fibrotic remodelling, whereas inflammation was greater in the HFpEF myocardium. We observed opposing features on calcium release, which was diminished in the HFrEF cardiomyocyte but enhanced in the HFpEF cardiomyocyte. Mitochondria were less polarized in both HFrEF and HFpEF cardiomyocytes, reflecting similarly impaired metabolic capacity. Hyperacetylation of cardiac proteins was observed in both models, but it was more accentuated in the HFpEF heart. Despite shared features, unique triggering mechanisms (neurohormonal overactivation in HFrEF vs. inflammation in HFpEF) appear to determine the distinct phenotypes of HF. The findings of the present research stress the need for further exploration of the differential mechanisms underlying each HF subtype, because they might require specific therapeutic interventions. Key points The mechanisms underlying heart failure with either reduced (HFrEF) or preserved (HFpEF) ejection fraction are often found to be different. Previous studies comparing pathophysiological traits between HFrEF and HFpEF have been conducted on animals of different ages and strains. The present research contrasted two age‐matched mouse models of non‐ischaemic HFrEF and cardiometabolic HFpEF to uncover divergent and shared features. We found that upon similar haemodynamic stress, the HFrEF heart experienced a more pronounced hypertrophic and fibrotic remodelling, whereas inflammation appeared to be greater in the HFpEF myocardium. Calcium release was diminished in the HFrEF cardiomyocyte and enhanced in the HFpEF cardiomyocyte. Mitochondria were comparably less polarized in both HFrEF and HFpEF myocytes. Hyperacetylation of proteins was common to both models, but stronger in the HFpEF heart. Casting light on common and distinguishing features might ease the quest for phenotype‐specific therapies for heart failure patients.

Computational investigation of the role of ventricular remodelling in HFpEF: The key to phenotype dissection

Computational Modeling of Ventricular Interdependence in Heart Failure

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Using Model‐Based Analysis and Physiology‐Informed Machine Learning to Refine the Stratification of Phenotypes in Heart Failure

Inversion of Left Ventricular Axial Shortening: In Silico Proof of Concept for Treatment of HFpEF

Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

Pathophysiological insights into HFpEF from studies of human cardiac tissue

Is atrial fibrillation in HFpEF a distinct phenotype? Insights from multiparametric MRI and circulating biomarkers

The role of T1 mapping and Extracellular Volume (ECV) in predicting cardiac reverse remodelling and response to Heart Failure with reduced Ejection Fraction (HFrEF) therapy

Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension

Distinguishing pathophysiological features of heart failure with reduced and preserved ejection fraction: A comparative analysis of two mouse models

Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge

Heart failure with improved ejection fraction: Beyond diagnosis to trajectory analysis

Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping

Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction

Cardiac reverse remodeling in a mouse model with many phenotypical features of heart failure with preserved ejection fraction: effects of modifying lifestyle

Morphometric, Hemodynamic, And Multi-Omics Analyses In Heart Failure Rats With Preserved Ejection Fraction

Left Atrial Roof Enlargement Is a Distinct Feature of Heart Failure With Preserved Ejection Fraction

Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction

Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction